Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LF3 |
Synonyms | |
Therapy Description |
LF3 is a small molecule that inhibits the interaction between Beta-catenin and TCF, resulting in reduced Wnt target gene expression, decreased migration of tumor cells, and potentially resulting in decreased tumor growth (PMID: 26645562). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LF3 | CTNNB1 Inhibitor 26 | LF3 is a small molecule that inhibits the interaction between beta-catenin (CTNNB1) and TCF, resulting in reduced Wnt target gene expression, decreased migration of tumor cells, and potentially resulting in decreased tumor growth (PMID: 26645562, PMID: 29786110). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | colon cancer | not applicable | LF3 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, LF3 decreased expression of Wnt target genes and reduced tumor growth in colon cancer cell line xenograft models derived from cells with high levels of Wnt signaling (PMID: 26645562). | 26645562 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|